Predictive factors for the presence of tumor cells in bone marrow and peripheral blood in breast cancer patients
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10312515" target="_blank" >RIV/00216208:11110/15:10312515 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/61989592:15110/15:33155546 RIV/00064165:_____/15:10312515
Výsledek na webu
<a href="http://dx.doi.org/10.4149/neo_2015_031" target="_blank" >http://dx.doi.org/10.4149/neo_2015_031</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2015_031" target="_blank" >10.4149/neo_2015_031</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Predictive factors for the presence of tumor cells in bone marrow and peripheral blood in breast cancer patients
Popis výsledku v původním jazyce
Simultaneous detection of disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) was shown to be associated with an especially poor prognosis and increased incidence of disease-related deaths in non-metastatic breast cancer patients. We analyzed the occurance of DTCs and CTCs in patients with primary breast cancer and evaluated the correlation of their presence with other prognostic markers and investigated the changes in DTCs/CTCs number at different time points during treatment. Blood of 50 patients with primary breast cancer were used for immunomagnetic separation and detection of circulating tumor cells using the commercial available system the AdnaTest Breast Cancer (TM) (AdnaGen GmbH, Langenhagen, Germany). Bone marrow aspirates from50 patients were analyzed for DTCs by immunocytochemistry using the pan-cytokeratin antibody conjugated with FITC (Monoclonal Anti-Cytokeratin antibody F3418, Sigma Aldrich). Our results support the use of DTCs/CTCs analysis in early brea
Název v anglickém jazyce
Predictive factors for the presence of tumor cells in bone marrow and peripheral blood in breast cancer patients
Popis výsledku anglicky
Simultaneous detection of disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) was shown to be associated with an especially poor prognosis and increased incidence of disease-related deaths in non-metastatic breast cancer patients. We analyzed the occurance of DTCs and CTCs in patients with primary breast cancer and evaluated the correlation of their presence with other prognostic markers and investigated the changes in DTCs/CTCs number at different time points during treatment. Blood of 50 patients with primary breast cancer were used for immunomagnetic separation and detection of circulating tumor cells using the commercial available system the AdnaTest Breast Cancer (TM) (AdnaGen GmbH, Langenhagen, Germany). Bone marrow aspirates from50 patients were analyzed for DTCs by immunocytochemistry using the pan-cytokeratin antibody conjugated with FITC (Monoclonal Anti-Cytokeratin antibody F3418, Sigma Aldrich). Our results support the use of DTCs/CTCs analysis in early brea
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Neoplasma
ISSN
0028-2685
e-ISSN
—
Svazek periodika
62
Číslo periodika v rámci svazku
2
Stát vydavatele periodika
SK - Slovenská republika
Počet stran výsledku
10
Strana od-do
259-268
Kód UT WoS článku
000362862400011
EID výsledku v databázi Scopus
2-s2.0-84943609394